Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6010 +/- SYH2051 vs Chemotherapy in EGFR-Expressing Advanced Solid Tumors and Breast Cancer
NCT06775236Phase 2Not yet recruiting
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Mar 2025
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 2 trial of CPO301 in solid tumor (advanced stage), breast cancer, sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
CPO301
03
Conditions
solid tumor (advanced stage)breast cancer
Beyond the preview
Go deeper on NCT06775236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06775236.